Try adjusting your type
14th October, 2009
European Survey on Standards of Care in paediatric oncology centres. J. R. Kowalczyk, M. Samardakiewicz, K. Pritchard-Jones, R. Ladenstein, S. Essiaf, E. Fitzgerald, G. Petrarulo, G. Vassal - EJC , Volume 61, pp 11-19
8th December, 2014
The purpose of this website is to provide good and clear information about the long-term effects of childhood cancer and to refer to the various late-effects outpatient clinics (LATER outpatient clinics) that exist in the Netherlands.
8th September, 2015
Cancer in young people is rare, but it is still a major health issue in Europe. Each year, more than 6,000 young people in Europe die of cancer. There are more than 300,000 European childhood cancer survivors (in 2020, they will be nearly half a million): two-thirds of them have some late side effects of treatment, that are severe and impact on the daily life of half of those affected.
Circulating tumor cells (CTCs) are cancer cells that have detached from a primary tumor and circulate in the bloodstream. These cells have the potential to spread cancer to other parts of the body through a process known as metastasis, making them a significant focus of cancer research and diagnosis.
Cancer remains one of the most pressing healthcare challenges of the 21st century. A key problem is metastasis, the spreading of cancer cells from the original tumor to other organs. Understanding this process is crucial for improving diagnostic and therapeutic strategies. In this context, circulating tumor cells (CTCs) have emerged as a key player. Let’s dive deeper into the world of CTCs and explore their relevance in cancer progression and therapy.
Circulating tumor cells (CTCs) are cancer cells that have detached from a primary tumor and circulate in the bloodstream. They constitute the “seeds” for the subsequent growth of additional tumors (metastases) in different body parts. Through the blood vessels, these cells can reach virtually any organ in the body, leading to a generalized spread of the disease.
CTCs originate from solid tumors, such as breast, lung, or prostate cancer. They are present in different stages, from precancerous lesions to advanced malignant tumors. Despite being a tiny fraction of the total number of blood cells, their role in cancer progression could be significant.
CTCs are not merely passive bystanders in cancer metastasis; rather, they actively participate in the process. They can adapt to survive in the blood, evade the immune system, and create a conducive microenvironment in the target organ, facilitating new tumor formation.
Given their major implications in cancer progression, early detection and analysis of CTCs are crucial. Multiple methods have been devised for this: blood sample analysis (liquid biopsy), specialized lab techniques such as CellSearch®, or innovative technologies like microfluidic devices.
Despite the advancements, detecting CTCs remains a challenge. Their rarity, differing shapes and sizes, and the difficulty isolating them from healthy blood cells pose significant hurdles. Improvements in detection methods are an active area of research.
Research has revealed a correlation between the number of CTCs and the prognosis of cancer patients. Higher counts suggest a more aggressive disease and worse prognosis. Hence, CTC count could serve as a powerful predictive tool in disease management.
CTCs offer promise as biomarkers for personalized therapy. By analyzing the molecular properties of CTCs, clinicians can tailor cancer treatments to individual patients, resulting in improved outcomes and reduced side effects.
CTCs are a potential therapeutic target in cancer treatment, focusing on hindering their ability to seed metastases. Researchers are investigating strategies to neutralize CTCs, such as blocking the pathways they use to enter target organs, or developing drugs that specifically target CTCs.
While the potential of CTCs in cancer therapy is immense, numerous challenges persist, including their identification, isolation, and targeting. However, with continuous research, we can hope for new and innovative applications of CTCs in the fight against cancer.
CTCs mark a breakthrough in our understanding of cancer metastasis and therapy. Their detection and analysis potentially revolutionize disease prognosis and treatment, offering a light at the end of the tunnel for patients navigating this devastating illness.
Circulating tumor cells (CTCs) are cancer cells that have detached from a primary tumor and circulate in the bloodstream. They are important as they can lead to metastasis, the spreading of cancer cells to different body parts.
CTCs are commonly detected with a blood sample analysis, known as a liquid biopsy. Other methods include specialized lab techniques like CellSearch® or innovative technologies like microfluidic devices.
Yes, higher numbers of CTCs in the bloodstream are often associated with a more aggressive disease state and worse prognosis.
By analyzing the molecular properties of CTCs, clinicians can design personalized treatments that are more likely to be effective, thus improving patients’ outcomes and reducing side effects.
The future may see improvements in the detection and isolation methods of CTCs, the development of drugs that specifically target CTCs, and advancements in personalized therapies based on CTC profiles.
Share it
You might also like
